Clinical Trial Data in Relapsed/Refractory Renal Cell Carcinoma

Video

Experts Matthew Campbell, MD, MS, and Brian Rini, MD, provide a brief review of recent clinical data in the setting of relapsed/refractory renal cell carcinoma.

Transcript:

Brian I. Rini, MD: Let’s transition to talk about refractory treatment…and switching between the doublets. If you have an ipilimumab-nivolumab progressor, are you giving a single-agent TKI [tyrosine kinase inhibitor] or are you giving an I/O [immuno-oncology]–TKI doublet?

Matthew T. Campbell, MD, MS: It’s a great question. We participated in Study 111, in which patients got lenvatinib-pembrolizumab in the second- or third-line setting, and the progression-free survival was around 11.5 months. Patients had a good treatment experience on ipilimumab-nivolumab until their cancer grew and did not have major toxicity. That approach is more appealing than a patient who had major toxicity with their maintenance phase of nivolumab. If patients had cabozantinib-nivolumab as frontline therapy, there are times when I’ll discuss lenvatinib-pembrolizumab as a second-line option. I’ll often still use single-agent cabozantinib or a combination of lenvatinib plus everolimus in a later-line setting and not pair it with I/O. The studies that we have ongoing—like the CONTACT-03 trial, which is cabozantinib with or without atezolizumab—will be helpful. We’re interested in seeing those data, as well as other studies comparing continuing I/O or not. I don’t think we have the answer to know if patients benefit from continuation on I/O after initial progression on I/O.

Brian I. Rini, MD: I agree. Single-agent TKI is the unexciting standard in that setting, but those trials with nivolumab too will provide insight. The practice is all over the map. The lenvatinib-pembrolizumab data in that setting is pretty impressive, but they’re single-arm data. I’m a believer that we need randomized data because we’ve been fooled with single-arm data before.

Transcript edited for clarity.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content